On November 4, Li Chuyuan, the chairman of Guangzhou Pharmaceutical Holdings Limited (GPHL), attended a discussion aimed at the common efforts of both Guangxi and the Guangdong-Hong Kong-Macao Greater Bay Area building an important node hub featuring dual circulation. He was invited as the enterprise representative of Guangdong Province to make a speech at the discussion.

Guangxi Baiyunshan Yingkang Pharmaceutical Ltd., one of the subsidiary enterprises of GPHL, was set up in Guangxi. The company ranks among the top ten in the region's pharmaceutical industry, with annual sales of 300 million yuan. Guangzhou Pharmaceuticals Co., Ltd., the largest commercial distribution monomer pharmaceutical company in China under the charge of GPHL, has established a branch in Guangxi to carry out drug distribution services. In addition, the Group's Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co., Ltd. and Wanglaoji Health Company have laid out production lines in Guangxi, deeply participating in the development of Guangxi's bio-medicine and health industry.

With its strong economic power, Guangdong is vigorously developing its TCM industry and promoting this industry to expand abroad. Guangxi has gradually served as an important bridgehead connecting China with ASEAN as well as countries along the Belt and Road. Moreover, Guangxi is also one of the top ten TCM production bases in the country, and has achieved positive results in developing the health industry.

In the future, GPHL will actively deepen its cooperation with Guangxi. In the field of Guangxi's Zhuang medicines, the Group will accelerate the construction of the Institute of Zhuang Medicine and focus on cultivating popular Zhuang medicine products.

Authors: Monica & Nancy (intern)

Editors: Olivia & Jerry